[Rivaroxaban: clinical pharmacology]

Area of Science:

• Pharmacology
• Hematology
• Clinical Trials

Background:

• Rivaroxaban is an oral, direct, and selective factor Xa inhibitor.
• It possesses favorable pharmacokinetic properties including high bioavailability and moderate half-life.

Purpose of the Study:

• To evaluate the efficacy and safety of rivaroxaban for venous thromboembolic (VTE) prophylaxis and treatment.
• To determine optimal dosing regimens for rivaroxaban in VTE management.

Main Methods:

• Phase II clinical studies involving 2787 patients for VTE prophylaxis post-orthopaedic surgery.
• Phase II clinical studies involving 1446 patients for VTE treatment.
• Assessment of pharmacokinetic characteristics, including bioavailability, Cmax, and half-life.
• Evaluation of renal and hepatic elimination pathways and potential drug interactions.

Main Results:

• For VTE prophylaxis, 10 mg once daily emerged as a potential optimal dose for Phase III evaluation.
• For VTE treatment, 15 mg twice daily for 3 weeks followed by 20 mg once daily was identified as a potential optimal regimen for further study.
• Rivaroxaban demonstrated no significant effect on factor IIa or platelets.
• No significant liver toxicity signals were observed across Phase II studies.

Conclusions:

• Rivaroxaban is a promising oral anticoagulant for VTE prophylaxis and treatment.
• Established dosing regimens require further evaluation in Phase III trials.
• Rivaroxaban exhibits a favorable safety profile with no significant observed liver toxicity.